Trial Details
RECRUITINGBasic Information
| Clinical ID | c858 |
|---|---|
| Identifier | NCT05928039 |
| Trial Title | PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease |
| Trial URL | Visit Original Page |
Study Information
| Study Results | NO |
|---|---|
| Conditions | Crohn Disease |
| Interventions | BIOLOGICAL: TNFa Antagonist - Infliximab|BIOLOGICAL: TNFa Antagonist - Adalimumab|BIOLOGICAL: Anti-IL12/23 or anti-IL23 - Ustekinumab|BIOLOGICAL: Anti-IL12/23 or anti-IL23 - Risankizumab|BIOLOGICAL: Anti-integrin - Vedolizumab IV|BIOLOGICAL: Anti-integrin - Vedolizumab IV and SC |
Participant Information
| Sponsor | University of Calgary |
|---|---|
| City | Alberta |
| Country/Region | Canada |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, OLDER_ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE4 |
Time Information
| Start Date | 2023-10-25 |
|---|---|
| Primary Completion Date | 2027-07-30 |
| Completion Date | 2028-12-31 |